MediBeaconTM Presents at 2013 InvestMidwest Venture Capital Forum
(KANSAS CITY, MO, April 4, 2013) – The 2013 edition of the InvestMidwest Venture Capital Forum featured a number of Medical Device innovations including a presentation from MediBeacon. Steve Hanley presented the MediBeacon story highlighting The Company’s focus on technology that would enable real-time, point-of-care monitoring of kidney function.
Assessment of renal function is a critical part of patient care. This need for a real-time renal function measurement is recognized by the National Institutes for Health, and is the subject of an on-going request to the medical research community for a solution.
The Company has invented a fluorescent tracer agent (APC-2) that is removed from the blood exclusively by the kidneys. MediBeacon’s non-invasive monitoring technology works in a similar fashion to pulse oximetry by using a light sensor placed on the skin.
InvestMidwest is a venture capital conference that showcases 40-45 companies from throughout the Midwest in the three industry tracks of life sciences, technology and food/ag/bioenergy. The 300+ attendees include investors from top venture capital firms. InvestMidwest has helped generate over $1 billion of investment in the past 13 years.
Further information on MediBeacon can be accessed at www.medibeacon.com
About MediBeacon, LLC:
MediBeacon LLC is a Medical Device company focused initially on kidney function monitoring in real-time. MediBeacon is housed within the Helix Center Biotech Incubator. Information regarding MediBeacon can be found at www.medibeacon.com.
# # #
Office – 314-269-5808
Email – email@example.com
1100 Corporate Square Drive
Helix Center, Suite 229
St Louis MO 63132